A Comparative Confirmatory Study of STN1012600 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
Status:
Recruiting
Trial end date:
2023-05-31
Target enrollment:
Participant gender:
Summary
To investigate whether the IOP lowering efficacy of STN1012600 ophthalmic solution 0.002% is
non-inferior to that of latanoprost 0.005% in subjects with POAG or OHT after treatment for 4
weeks.